Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate

Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rausch, Jessica L., Boichuk, Sergei, Ali, Areej A., Patil, Sneha S., Lee, Donna M., Brown, Matthew F., Makielski, Kathleen R., Liu, Ying, Taguchi, Takahiro, Kuan, Shih-Fan, Duensing, Anette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://www.ncbi.nlm.nih.gov/pubmed/27965460
http://dx.doi.org/10.18632/oncotarget.13882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://www.ncbi.nlm.nih.gov/pubmed/27965460
http://dx.doi.org/10.18632/oncotarget.13882

Ejemplares similares